Healthcare / Medical DevicesNasdaqCM
$2.03
-0.04 (-1.93%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.9M · quality 64.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$65M
P/E
N/A
•EV/EBITDA
N/A
•ROE
132.2%
↑Gross Margin
45.4%
↓Debt/Equity
-1.76
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-50.5%
FCF / Net income
1.31x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.6M · net income $-7.6M · FCF $-9.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $19.6M | $19.6M | $29.6M | $18.1M | $25.4M | — | — |
| Net Income | $-7.6M | $-7.6M | $-15.2M | $-20.9M | $-2.9M | $-2.1M | — |
| EBITDA | $-4.5M | $-4.5M | $-11.5M | $-20.1M | $-2.1M | — | — |
| EPS | -0.29 | -0.29 | -0.85 | -1.48 | -0.19 | — | — |
| Gross Margin | 45.4% | 45.4% | 44.9% | 43.6% | 42.7% | — | — |
| Operating Margin | -43.8% | -43.8% | -22.3% | -71.9% | -10.4% | — | — |
| Net Margin | -38.5% | -38.5% | -51.2% | -115.5% | -11.5% | — | — |
| Balance Sheet | |||||||
| Debt/Equity | -1.76 | -1.76 | -0.65 | -0.75 | 0.10 | — | — |
| Current Ratio | 0.75 | 0.75 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-9.9M | $-9.9M | $-9.2M | $-13.2M | $-1.2M | — | — |
| Returns | |||||||
| ROE | 132.2% | 132.2% | 209.0% | 1220.2% | -24.3% | -15.6% | — |
| Valuation | |||||||
| P/B | — | — | — | — | 13.29 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -33.6% | -33.6% | 63.8% | -28.8% | — | — | — |
| EPS Growth | 65.9% | 65.9% | 42.6% | -697.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+26.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.85 → -0.29
Residual
+26.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.